Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

CAR-T therapy in multiple myeloma: research blind spots [Video]

CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Future research directions for breast cancer [Video]

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses what he thinks are the most important trials and future research directions in ER-positive, HER2-positive, and triple-negative breast cancer. Oral selective estrogen receptor degraders (SERDs) were an exciting topic at SABCS 2021, with promising data being presented. Dr Curigliano also discusses the NATALEE (NCT03701334) and DESTINY-Breast06 (NCT04494425) trials. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines [Video]

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of a study investigating optimal treatment sequencing in multiple myeloma. With the available options for treatment expanding rapidly, determining the best strategies for upfront treatment and subsequent lines of therapy is of critical importance. In this analysis, the clinical value of daratumumab (DARA) first line compared to later lines was examined in patients with newly diagnosed transplant-ineligible multiple myeloma, since it is unclear where it performs optimally. It was shown that using DARA, lenalidomide, and dexamethasone (D-Rd) first line substantially improved overall survival compared with delaying DARA-based treatment until second line. Due to higher attrition rates in second line and beyond, the results demonstrate that achieving the longest possible progression-free survival in first line is key to optimize overall survival outcomes and therefore, saving DARA to later lines is a suboptimal approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of immunotherapy in multiple myeloma [Video]

Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Recent breast cancer updates from SABCS 2021 [Video]

Nadeem Bilani, MD, Mount Sinai Morningside, New York, NY, provides an overview of recent updates in breast cancer presented at the San Antonio Breast Cancer Symposium (2021) hybrid meeting, including the evaluation of novel antibody-drug conjugates, as well as further updates on the use of immunotherapy in breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

MASTER: Dara-KRd in patients with multiple myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma [Video]

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses concurrent pembrolizumab, an anti-PD⁠-⁠1 monoclonal antibody, with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with classical Hodgkin lymphoma (cHL). The treatment regimen displayed promising efficacy and safety and in patients. However, the interim-positron emission tomography (PET) scan results did not align with the high progression-free survival rates observed, and cell-free DNA (cfDNA) may predict outcomes more accurately. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Molecular heterogeneity in HER2+ breast cancer and predicting outcomes [Video]

Aleix Prat, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, provides an overview of molecular heterogeneity in HER2+ breast cancer, discussing biological features linked to clinical outcomes including intrinsic subtyping. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

PD-L1 inhibitors in r/r Hodgkin lymphoma [Video]

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, describes current treatment options for patients with relapsed/refractory Hodgkin lymphoma who have progressed or are ineligible for transplant. Whilst PD-L1 inhibitors such as pembrolizumab and nivolumab have shown to efficacious in patients, producing durable responses remains a barrier. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Treating TP53 mutant mantle cell lymphoma in the BOVen trial [Video]

Patients with TP53 mutant mantle cell lymphoma (MCL) represent an unmet need and there care no current frontline standard of care for these high risk patients. Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, presents results from the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant MCL. Two cycles of zanubrutinib and obinutuzumab were initially administered, followed by venetoclax. The regimen was well tolerated and displayed preliminary efficacy, with a majority of patients being in ongoing remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.